High circulating levels of cardiovascular hormones/peptides in cancer patients are linked to shorter survival, regardless of disease type and stage of progression, reveals research published online in the journal Heart.
Leading primary care professionals and cancer experts warned at the Royal College of General Practitioners (RCGP) annual congress in Glasgow last weekend (October 1-3) that GPs will not be able to cope with the rising demand for cancer care in high-income countries — predicted to double within the next 15 years.
A new study of alcohol use in countries of all income levels shows that current use increases the risk of alcohol-related cancers and injury, with no reduction in risk of mortality or cardiovascular disease overall.
In prostate brachytherapy, the radiation source is placed close to the tumour, Gary Culliton reports in his latest Clinical Update. In essence, brachytherapy is the oldest form of radiation treatment and the technique now used in Ireland was pioneered 40 years ago in the American north west.
Abiraterone acetate is now reimbursed on the high-tech drug scheme for men with metastatic castration-resistant prostate cancer (mCRPC) post-androgen deprivation therapy (ADT).
“It is known that men who have prostate cancer are more likely to die of their disease if they are overweight or obese than if they are of a healthy weight,” according to Dr Stephen Finn, Associate Professor in Histopathology and Morbid Anatomy in Trinity College Dublin and Consultant Pathologist at St James’s Hospital.
Two new studies, both published in The Lancet, suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer.
New Irish research published in BMJ Open has found that young people aged 16-17 years old believe standardised packs to be less attractive and their cigarettes to be more harmful than packs with EU Tobacco Products Directive (TPD) labels, which includes picture and text warning covering 65 per cent of the packages.
In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.
In the years to come, personalised medicine will be the goal, Gary Culliton reports in his latest Clinical Update. It is a promising area: now much effort is devoted to studying combinations of different therapies.